Biomea Fusion Inc

NASDAQ BMEA

Data sourced from

and

Download Data

Biomea Fusion Inc Debt to Asset Ratio for the quarter ending March 31, 2024

Biomea Fusion Inc Debt to Asset Ratio is NA for the quarter ending March 31, 2024. The debt to asset ratio measures the proportion of a company's total assets that are financed by debt. It is calculated by dividing total debt by total assets. This ratio indicates the extent to which a company relies on debt financing to support its asset base. A higher ratio suggests a higher level of leverage and potential financial risk.

NASDAQ: BMEA

Biomea Fusion Inc

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road, Redwood City, CA, United States, 94063
Employees	110
Sector	Healthcare
Industry	Biotechnology

Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends